Boron agents reach previously untreatable tumors

Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs target ASCT2, a transporter ...

New mRNA platform remains effective even in aging and obesity

Since the COVID-19 pandemic, mRNA vaccines have gained attention as a next-generation pharmaceutical technology. mRNA therapeutics work by delivering genetic instructions that enable cells to produce specific proteins for ...

How one receptor can help—or hurt—your blood vessels

Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels—one inflammatory and one protective. This protein, a cell-surface receptor called ...

Approved IV drug reduces lupus symptoms, clinical trial finds

An already-approved IV drug significantly reduces the symptoms of lupus, a new clinical trial showed. More than three-quarters of lupus patients taking obinutuzumab (Gazvya) had a significant improvement in their symptoms ...

page 29 from 40